Astrana Health
ASTH
37.14
+0.14
+0.38%
Astrana Health
US · ASTH
#2768 by market cap
Listed 1970
37.14
+0.14
+0.38%
Live - 5344 symbols - heartbeat 7s ago
· 2026-10-07 19:54
After-hours
37.14
0.00%
- Market cap
- 2.07B
- P/E (TTM)i
- 45.29
- P/Bi
- 2.49
- EPSi
- 0.46
- Div yieldi
- 0.00%
- 52W posi
- 57%
Reader sentiment
Are you bullish or bearish on ASTH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.9 percentage points.
Institutional ownership
- Held by institutions
- 76.71% -2.92pp
- Institutions
- 256 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund54.22%
Private Company13.88%
Individual/Insider10.73%
Hedge Fund4.75%
Public Company2.51%
Government Pension Fund1.09%
Family Office/Trust0.17%
Other12.58%
Top holders as of 2026-06-30
BlackRock
13.48% · 6.90M sh
Allied Physicians of California IPA
13.35% · 6.83M sh
Vanguard Portfolio Management, LLC
5.09% · 2.61M sh
Vanguard Capital Management, LLC
4.40% · 2.25M sh
Brandon Sim
3.69% · 1.89M sh
State Street Global Advisors
3.40% · 1.74M sh
325 Capital, LLC
3.15% · 1.61M sh
Thomas Lam
3.04% · 1.56M sh
Dimensional Fund Advisors
2.87% · 1.47M sh
Kenneth Sim
2.85% · 1.46M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 20 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Brandon Sim | Co-Chief Executive Officer | 3.69% |
| Thomas Lam | President, Co-CEO & Director | 3.04% |
| Kenneth Sim | Executive Chairperson | 2.85% |
| Chandan Basho | Chief Strategy Officer, CFO & Corporate Secretary | 0.31% |
| Dinesh Kumar | Chief Medical Officer | 0.31% |
| Linda Dong | Director | 0.19% |
| Matthew Mazdyasni | Director | 0.08% |
| David Schmidt | Independent Director | 0.07% |
| John Chiang | Independent Director | 0.07% |
| Mitchell Kitayama | Lead Independent Director | 0.05% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | John Vong | Chief Accounting Officer | Sale to Issuer | -96 | $38.35 |
| 2026-09-04 | Brandon Sim | Co-Chief Executive Officer | Sale to Issuer | -7,163 | $38.47 |
| 2026-09-04 | Chandan Basho | Chief Strategy Officer, CFO & Corporate Secretary | Sale to Issuer | -1,790 | $38.47 |
| 2026-08-30 | Mitchell Kitayama | Lead Independent Director | Sale to Issuer | -8,500 | $37.09 |
| 2026-08-13 | David Schmidt | Independent Director | Derivative Exercise and Sale | -20,000 | $5.00–38.59 |
| 2026-08-06 | John Vong | Chief Accounting Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-08-06 | Glenn Sobotka | Chief Accounting Officer | Sale to Issuer | -11,793 | -- |
| 2026-06-26 | Brandon Sim | Co-Chief Executive Officer | Sale to Issuer | -1,093 | $44.51 |
| 2026-06-09 | Weili Dai | Independent Director | Other Acquisition | +4,525 | -- |
| 2026-06-09 | Mitchell Kitayama | Lead Independent Director | Other Acquisition | +4,991 | -- |
| 2026-06-09 | David Schmidt | Independent Director | Other Acquisition | +4,525 | -- |
| 2026-06-09 | John Chiang | Independent Director | Other Acquisition | +4,525 | -- |
| 2026-06-09 | Matthew Mazdyasni | Director | Other Acquisition | +4,525 | -- |
| 2026-06-09 | Linda Dong | Director | Other Acquisition | +4,525 | -- |
| 2026-05-15 | Chandan Basho | Chief Strategy Officer, CFO & Corporate Secretary | Sale to Issuer | -8,155 | $38.26 |
| 2026-04-13 | Chandan Basho | Chief Strategy Officer, CFO & Corporate Secretary | Sale to Issuer | -3,870 | $29.07 |
| 2026-04-05 | Thomas Lam | President, Co-CEO & Director | Other Acquisition | +41,667 | -- |
| 2026-04-05 | Kenneth Sim | Executive Chairperson | Other Acquisition | +100,000 | -- |
| 2026-04-05 | Brandon Sim | Co-Chief Executive Officer | Other Acquisition | +201,056 | -- |
| 2026-04-01 | Chandan Basho | Chief Strategy Officer, CFO & Corporate Secretary | Sale to Issuer | -2,092 | $25.05 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.